{"id":995,"date":"2021-06-04T08:36:02","date_gmt":"2021-06-04T06:36:02","guid":{"rendered":"https:\/\/www.dgrpharma.com\/?p=995"},"modified":"2025-09-09T21:20:12","modified_gmt":"2025-09-09T19:20:12","slug":"publications","status":"publish","type":"post","link":"https:\/\/www.dgrpharma.com\/cms19\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"<p>View some publications in which DGr Pharma is involved&#8230;<\/p>\n<ul>\n<li><a href=\"https:\/\/ir.pharvaris.com\/static-files\/33217945-6893-4f49-8a93-c80ea6fb2a31\" target=\"_blank\" rel=\"noopener noreferrer\">Bradykinin Challenge Provides Surrogate Endpoints For Hereditary Angioedema TreatmentUsing Bradykinin-B2-Receptor Antagonists<\/a><\/li>\n<li><a href=\"https:\/\/ir.pharvaris.com\/static-files\/0361cd85-6000-490b-932b-d305e1f3ca1b\" target=\"_blank\" rel=\"noopener noreferrer\">PHA-022121, a Selective Bradykinin-B2-Receptor Antagonist, Is Safe and Shows Rapid Oral Bioavailability in Humans<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>View some publications in which DGr Pharma is involved&#8230; Bradykinin Challenge Provides Surrogate Endpoints For Hereditary Angioedema TreatmentUsing Bradykinin-B2-Receptor Antagonists PHA-022121, a Selective Bradykinin-B2-Receptor Antagonist, Is Safe and Shows Rapid Oral Bioavailability in Humans<\/p>\n","protected":false},"author":3,"featured_media":1222,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-995","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/posts\/995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/comments?post=995"}],"version-history":[{"count":8,"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/posts\/995\/revisions"}],"predecessor-version":[{"id":1221,"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/posts\/995\/revisions\/1221"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/media\/1222"}],"wp:attachment":[{"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/media?parent=995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/categories?post=995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/tags?post=995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}